Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH10-10-0631
Issue: 2011: 105/6 (June) pp. 933–1123
Pages: 1072-1079

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery

J. Windyga (1), M. von Depka-Prondzinski (2), on behalf of the European Wilate® Study Group

(1) Institute of Haematology and Transfusion Medicine, Warsaw, Poland; (2) Werlhof Institute, Hannover, Germany

Keywords

surgery, von Willebrand factor, factor VIII, von Willebrand disease, Wilate®

Summary

The aim of this study was to assess the efficacy of Wilate®, a new generation, plasma-derived, high-purity, double virus-inactivated von Willebrand factor (VWF) and factor VIII (FVIII) concentrate (ratio close to physiological 1:1) in the perioperative management of haemostasis in von Willebrand disease (VWD). Data for VWD patients who received Wilate® for perioperative management were obtained from four European, prospective, open-label, non-controlled, non-randomised, multicentre phase II or III clinical trials. A total of 57 surgical procedures were performed (major: n = 27; minor n = 30) in 32 patients. The majority of patients (n = 19, 59.4%) had type 3 VWD, 9 (28.1%) had type 2 VWD and four (12.5%) had type 1 VWD. During major surgery, median daily FVIII dose and mean number of infusions were 25 IU•kg-1 FVIII (VWF:RCo ~23 IU•kg-1) and 11.0, respectively. Corresponding values for minor surgery were 35 IU•kg-1 (VWF:RCo ~32 IU•kg-1) and 1.5. The efficacy of Wilate® was rated by the investigator as excellent or good in 51 of 53 (96%) procedures. Tolerability was rated as very good or good in 100% of major surgeries (27 of 27) and minor surgeries (29 of 29). Wilate® is an effective and well-tolerated VWF/FVIII replacement therapy in the perioperative management of haemostasis in patients with VWD. It can be administered at a similar FVIII dose, but at a lower VWF dose, as compared to older generation products. Clinical benefits were shown in a population with a high proportion of type 3 VWD patients.

You may also be interested in...

1.

Steven W. Pipe

Thromb Haemost 2008 99 5: 840-850

http://dx.doi.org/10.1160/TH07-10-0593

2.
Carolyn M. Millar1, Anne F. Riddell1, Simon A. Brown1, Richard Starke2, Ian Mackie2, Derrick J. Bowen3, P. Vincent Jenkins1, Jan A. van Mourik4

Thromb Haemost 2008 99 5: 916-924

http://dx.doi.org/10.1160/TH07-09-0565

3.
Alessandra Casonato, Francesca Sartorello, Elena Pontara, Lisa Gallinaro, Antonella Bertomoro, Maria Grazia Cattini, Viviana Daidone, Maryta Szukowska, Antonio Pagnan

Thromb Haemost 2007 98 6: 1182-1187

http://dx.doi.org/10.1160/TH07-05-0347